Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

Core Laboratories Inc.

CLBNYSEEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the “Company”) of his intention to resign as a director of the Company effective October 1, 2026. Subsequently, on August 25, 2026, Mr.…

Filed Aug 25, 2026Accepted Aug 25, 2026, 4:51 PM EDTCIK 1958086Accession 0001193125-26-365271
Share

Company context

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by DISCIPLINED GROWTH INVESTORS INC /MN regarding Core Laboratories Inc. /DE/Nov 16, 2026
  2. SCHEDULE 13G/A - filed by EARNEST PARTNERS LLC regarding Core Laboratories Inc. /DE/Nov 13, 2026
  3. 10-Q filingOct 30, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureOct 28, 2026
  5. 4 filingOct 5, 2026

Registered securities in this filing

CORE LABORATORIES INC. · 8-K · Filed 2026-08-25

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock (par value $0.01)

Symbol
CLB
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: C_e794d582-b20b-4cf1-9c51-f8ba63ae5ef7

Dimensions: Not supplied

Accession 000119312526365271 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the “Company”) of his intention to resign as a director of the Company effective October 1, 2026. Subsequently, on August 25, 2026, Mr. Temeng confirmed his resignation by letter addressed to the Board of Directors. Mr. Temeng serves as Chairman of the Nominating Committee and as a member of the Compensation Committee. As stated in his letter, Mr. Temeng’s resignation was due to a disagreement with the Board of Directors regarding the strategic direction of the Company and certain governance practices. The Board of Directors believes that Mr. Temeng’s primary disagreement involves the manner in which the Company is conducting succession planning within the organization, a process supported by a majority of the members of the Board. With respect to strategic direction, the Board of Directors believes Mr. Temeng has concerns with the Company’s research priorities. A copy of Mr. Temeng’s resignation letter to the Board of Directors is filed as Exhibit 17.1 to this Form 8-K. The Company provided Mr. Temeng with a copy of this Form 8-K and an opportunity to state whether he agrees with the statements herein and, if not, the respects in which he disagrees. Throughout his more than five years of service on the Board, the Company has appreciated Mr. Temeng’s contributions, commitment and leadership.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.